Patients Bringing awareness to Brain Tumour Month, personally This Brain Tumour Awareness Month, Inventus' Jim Michel reveals how living with a benign brain tumour has influenced his life.
News Servier snaps up cancer biotech Day One in $2.5bn deal Servier has made a takeover offer for Day One and its fast-growing glioma therapy Ojemda, as it pitches to drive sales above €10bn by 2030.
News CHMP backs Ipsen drug for childhood brain cancer Ipsen's Ojemda is on course to become the first targeted medicine in the EU for some children with a form of brain cancer known as low-grade glioma.
R&D How synthetic data is overcoming privacy challenges in healt... The healthcare industry is saturated in data, but accessing the right data, at the right time, remains a persistent challenge.
News Jazz gets FDA okay for Chimerix brain cancer drug Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations.
News Jazz swings further into cancer with Chimerix takeover Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
